期刊
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
卷 40, 期 10, 页码 1325-1329出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/03639045.2013.819880
关键词
Alendronate; modeling; men; pharmacokinetics; plasma; urine
资金
- Korea Science and Engineering Foundation (KOSEF) grant - Korean government (MOST) [R01-2007-000-20805-0]
- National Research Foundation of Korea [R01-2007-000-20805-0] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
The study of pharmacokinetics of alendronate has been hampered by difficulties in accurately and reproducibly determining their concentrations in serum and urine. Thus, pharmacokinetic characteristics of alendronate have been described in many reports based on urinary excretion data; and plasma pharmacokinetics and the simultaneous pharmacokinetic models of alendronate in plasma and urine are not available. The aims of this study were to measure alendronate concentration in plasma and excretion in urine concurrently and to develop compartmental pharmacokinetic model using urine data. In open-label, single-dose pharmacokinetic study, 10 healthy male volunteers received oral dose of alendronate (70mg tablet). Blood and urine alendronate concentrations were determined using validated high-performance liquid chromatography method. Non-compartmental analysis was performed using WinNonlin program (Pharsight Inc., Apex, NC). A one-compartment pharmacokinetic model was applied to describe pharmacokinetics of alendronate. A peak plasma alendronate concentration of 33.10 +/- 14.32 ng/mL was attained after 1.00 +/- 0.16 h. The cumulative amount of alendronate excreted in urine and peak excretion rate were 731.28 +/- 654.57 mu g and 314.68 +/- 395.43 mg/h, respectively. The model, which included first-order absorption rate for oral dosing, showed good fit to alendronate data obtained from plasma and urine. The absorption rate constant was 2.68 +/- 0.95 h(-1). The elimination rate constants K-urine and Knon-ur were 0.005 +/- 0.004 h(-1) and 0.42 +/- 0.08 h(-1), respectively. The pharmacokinetics of alendronate in plasma and urine of healthy men can be predicted using one-compartment model, and thus the behavior of drug in plasma can be estimated from urinary excretion data.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据